Biovac
Mike Begg is a seasoned professional with extensive experience in biotechnology and project management. Since May 2006, Mike has held multiple roles at The Biovac Institute, including Manager of Product Support and Technology Transfer, Operations Advisor, PMO and Project Portfolio Manager, and Programme Manager for projects such as the Cape Biologicals Hib Project. Responsibilities include overseeing infrastructure projects, guiding operations in project selection and management, and ensuring successful coordination of the project portfolio. Prior to this, Mike served as Head of the Biopolymer Unit and Research Scientist at Ribotech (Pty) Ltd from January 1997 to April 2006, where Mike was instrumental in establishing a biotechnology pilot plant. Mike holds an M.Sc Med in Medical Biochemistry and a B.Sc Med (Hons) from the University of Cape Town, along with a B.Sc in Biochemistry from the University of KwaZulu-Natal.
This person is not in any teams
Biovac
1 followers
Biovac was founded in 2003 to revive and restore South Africa’s vaccine manufacturing capabilities. We are an African based manufacturer contributing towards filling the gap that exists in the lack of African vaccine manufacturing capability. We recognise that we’ll only achieve this if we match scientific innovation through local biotechnology skills with the most advanced manufacturing technology and global partnerships. We work closely with local academic institutions, global pharmaceutical companies, the public sector as well as private sector. Some of our achievements are described below: We manufacture highly advanced vaccines on behalf of leading international biopharmaceutical companies. Biovac is licensed to manufacture a fully liquid hexavalent vaccine from Sanofi that targets and protects against six childhood diseases. In 2021, we envisage to start the manufacture of a multivalent pneumococcal conjugate vaccine from Pfizer. We supply over 15-million doses of vaccines a year in South Africa and neighbouring countries under strict cold chain conditions. We have built inhouse product development capability and technologies and have successfully out-licensed one of our technologies to international manufacturers. We are working to establish new safeguards against pathogens like group B streptococcus bacteria, a rising cause of sepsis and meningitis in newborns. To do this vital work, we rely on sophisticated technology and, above all, the skills and dedication of more than 350 highly trained team members. Along with our partners, we’ve invested over R800 million in infrastructure and skills development at our manufacturing facilities in Cape Town. These investments are resulting in estimated benefits of more than R500-million a year to the national economy.